National Research Council of Canada

Other

Lakshmi Krishnan

Dennis M Whitfield

Kevin Young

Jamshid Tanha

Wah Yau Wong

Baomin Tian

Marni Diane Uger

Heman Lap Man Chao

G Dennis Sprott

Subash Sad

Fanny Tzelepis

Valeria Alcon

Dennis Sprott

Kevin G Young

A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.

CEACAM6 CAR immune cells to treat cancers

A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8and CD4T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50. 

Sulfated-glycolipids as adjuvants for vaccines

Modified non-human mammalian hepatoma cell lines that express hepatitis C virus (HCV) antigens and which are capable of generating tumours in a syngeneic animal model are provided. The cell lines are generated by genomic integration of an expression construct that comprises one or more HCV antigen-encoding sequences under the control of a constitutive promoter. The expression construct further comprises a selectable marker and a reporter gene under the control of the same promoter. The cell lines are useful for testing prophylactic and therapeutic vaccines against HCV either in vitro or in vivo.

Animal models, cell lines and methods for screening hepatitis C virus vaccines

The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumor antigen. Methods of imparting immunity using the recombinant bacterium are also provided.

Recombinant bacterium and uses thereof

Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as saturated archaeol and caldarchaeol are obtained from appropriate Archaea. Archaeosome lipid vesicles are formulated from the synthetic lipids selected to serve as antigen carriers that target antigen-presenting cells and promote an appropriate immune response to the antigen.

Synthetic archaeal glycolipid adjuvants

Growing community of inventors

Ottawa, Canada

Lakshmi Krishnan